Entry Inhibitors in HIV Therapy details the current status of this
relatively new and very dynamic class of inhibitors, appealing to both
the clinician and basic research scientist. A unique overview of
obstacles and accomplishments is presented. The book features chapters
that explain the challenges of high sequence diversity in the viral
envelope gene for the development and use of entry inhibitors, the
clinical utility of virus phenotyping, the development of this class of
inhibitors as microbicidal therapy, and the success story of enfuvirtide
from the bench to FDA approval. Both basic research findings and results
of clinical studies are covered and linked together by a diverse panel
of experts in the field.